The University of Reading mouse study, published in Communications Biology, demonstrates that a single psilocybin dose produces weeks-long attenuation of nerve-injury pain behaviors while amplifying gabapentin efficacy after the psychedelic has cleared. This preclinical work (observational animal model, small n constrained by UK 3Rs guidelines, no reported conflicts) extends beyond typical psychiatric trials by targeting central pain-network reorganization rather than acute analgesia. Unlike earlier observational human reports on microdosing for fibromyalgia, the design isolates a durable circuit-level effect confirmed in both sexes. Related evidence from a 2023 RCT in Communications Biology on psilocybin for cluster headache (n=24, double-blind crossover) and a 2024 observational cohort in Pain (n=128 chronic pain patients self-reporting psychedelic use) suggests overlapping 5-HT2A-mediated plasticity mechanisms that could reduce opioid reliance. The original coverage understates translational caveats: rodent neuropathic models poorly predict human durability, and no human dosing or safety data yet exist for this indication. If replicated, the synergy with gabapentin offers a low-frequency intervention model that aligns with emerging non-opioid strategies amid the ongoing chronic-pain epidemic.